Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seasoned executive team with a track record of medical biotechnology innovation...
To deliver on its mission, MyMD has assembled a superb team of clinicians, experienced drug developers, US FDA / regulatory experts, patent attorneys, and business executives. The team is drawn from a variety of institutions including but not limited to Organon, Regeneron, IQVIA (formerly Quintiles), Bain & Company, and Banner Witcoff. We continue to add clinical and scientific talent to support our research and the discovery of new therapies.
MyMD Pharmaceuticals Begins Trading on Nasdaq..
.
FLASH... FLASH... Phase II Trial results expected by year end
.
“The listing of our shares on the Nasdaq marks a significant milestone for the company, in combination with our upcoming phase II trial and our clinical development pipeline, all of which should lead to increased visibility in the near term for our investors..
.
https://www.businesswire.com/news/home/20210419005502/en/MyMD-Pharmaceuticals-Begins-Trading-on-Nasdaq
MyMD Pharmaceuticals Scientific Advisory Board
https://www.biospace.com/article/releases/akers-proposed-merger-partner-mymd-pharmaceuticals-announces-formation-of-scientific-advisory-board/
Can the name of this board be changed?
From: Akers Biosciences Inc. (AKER)
To : MyMD Pharmaceuticals (MYMD)
???
"Significantly increasing lifespan" —MyMD Pharmaceuticals
Bid/Ask interesting - chaotic for awhile looks like
MYMD Begins Trading this Morning
https://www.mymd.com
Extremely reasonable!!
Reason for the phase 2 trial target?
Treatment of depression was stated as the objective.
Perhaps the reason for that target is that it presented the fastest path to FDA approval.
Once approved as a treatment for depression knowledgeable doctors can prescribe it for other purposes.
Reasonable guess or not?
Merger approved. MYMD to start trading April 19, 2021
http://www.akersbio.com/investor-center/news/2021/04-16-2021-173008890
When I said "Fasten your seat belts!", I was thinking "UP" not "DOWN"!
Today's action sure didn't reflect the last 2 days news releases!
Today's announcement seemed to miss most of the reasons for buying MYMD (through AKER). Perhaps deliberate? May have created a buying opportunity.
WHAT HATH JONNIE WROUGHT !! I am blown away by the quality of this Scientific Discovery Board. It not only includes a healthy number of Johns Hopkins doctors, but also includes MINDMED and Eurofins Discovery.
Hopefully, MyMD Pharmaceuticals will become a public reality by the end of this week, and we can begin to share this awesome story much more widely than has been the case up to now.
Fasten your seat belts!
Yes, we go ...
http://otp.investis.com/clients/us/akers_bioscience/SEC/sec-show.aspx?Type=html&FilingId=14865144&CIK=0001321834&Index=10000
Same thing. Different source and format.
knuts,
The main difference is MyMD-1 is ready to use now and has been completed pre-clinical and phase-1 and already entered into Phase-2.
Where as Cohbar is still at initial stages and long way to go.
.
Once Phase-2 is complete, which is by the year end, no one can compete with MyMD in those line. My two cent..
Hard to believe! On 03/11/21 Jonnie and friends created yet another FL private company, this one called Arica Pharmaceuticals. Beginning to look like they are creating a company for each potential application of the isomyosmine and Supera families!
From a competitive point of view I see Jonnie as being ahead because he is ready to begin significant Phase 2 studies, and has chosen company and product names (MyMD Pharmaceuticals and MYMD-1) that are easily recognized and remembered.
Looks interesting. Complimentary rather than competitive, except in a very broad sense in which all health restoring drugs are competitive.
Those who are serious about MyMD Pharma should take a look at CohBar. (CWBR) Looks like it could be direct competition for MyMD. They are making many of the same claims as MyMD makes for MYMD-1.
Correction of my previous post. Jonnie Williams appears more than once in the document describing the merger. My earlier search seems to have been defective.
If a new pdf of the document is made, at least on a Mac, it becomes possible to cut text from it and paste it elsewhere.
A section beginning on page 122 describes the reasons for the merger from the point of view of each of the companies.
Today I received a request for my votes (virtually) at the next AKER board meeting, scheduled for April 15, 2021.
It was suggested that I should first read an accompanying background document of somewhere around 400 pages. It contains things that look interesting. I'll read some of it.
Under this heading: "The obligation of Akers to complete the merger is subject to the satisfaction or waiver of the following additional conditions:" This appears as one of the conditions:
Leif, Agree. But, Shelf offerings can dilute existing shares considerably if the offering comes from the company because new shares are being created. Why a Shell company AKERS is doing this by misguiding public is my concern.
You may be right, but not this is not an announcement of an actual raise, it is an announcement of permission to raise should they need to do so. Nothing is for sale yet. This is how I understand a "shelf offering." Please correct this if I'm wrong.
$AKER: The reasons mentioned to raise $100 millions is full of lies.
Issuing another public offering (in the last minute of merger with MyMD pharma) to raise for non-existing covid-19 vaccine is federal crime. Raising $100 Millions in the name of agreement with a non performing Premas (which is an INDIA company) is federal fraud. Raising the money in the last minute of merger is another definitely unacceptable & its a BIG fraud, very bad for investors.
The AKERS present directors have to face the consequences...
Something is not right.
Could be wrong, of course, but I think the merger with MYMD will succeed. There's too much benefit here for AKER to allow it to fail. Main reason for my confidence is that I think Jonnie Williams' work and intentions are genuine. His long-standing collaboration with Johns Hopkins researchers is encouraging.
After the merger, the surviving company will be MYMD, and the stock listing will be MYMD. I'm optimistic that this will be a success.
Lief,
Do you think the merger is going to happen? or fail?
If you see the track record of Akers, its all manipulations.
Please advise.
Anyone interested in the future of AKER should read this: https://www.mymd.com/
Just posted by knuts4oe.
Here is the latest website for MyMD for anyone who has not seen it. Contains a thorough explanation of what MyMD is all about!
https://www.mymd.com/
Williams, Hopkins, McNulty, O'Donnell
Jonnie Williams RSR
https://duckduckgo.com/?q=WILLIAMS+JONNIE+RSR&t=osx&ia=web
This search finds many Jonnie Williams related companies, most (or all) at the following address, associated with Johns Hopkins.
Many (or all?) Jonnie Williams companies use this as their principal address:
Stockholder meeting, Apr 15, & merger information
https://www.businesswire.com/news/home/20210322005123/en/
Very interesting. Thanks!
As has been revealed, Supera Pharma will be purchased by MyMD Pharma just before the final closing of the merger, for nearly 34 million MyMD Pharma shares, thus becoming an integral part of the new company. We have also become aware that a new private corporation was formed in FL this year under the name Nemo Life Sciences Inc., whose principal address is the suite in the Rangos Life Sciences Bldg on the Johns Hopkins campus where MyMD Pharmrceuticals is now located. A search of the internet indicated that NEMO is an integral part of the process of bone replacement and repair.
If that isn't enough, I have learned that another 10 (ten) private companies have been formed in FL this year by Jonnie and associates, all of which have as their principal address the same suite in Baltimore that MyMD Pharma occupies! They are,
PSYCHEDELX INC DOPAMYNE INC OXYGENE INC MIRAVID INC
ICENE INC KETAMIR INC COTIMINE INC SETACYBIN INC
REVLIMIR INC NYME INC
Can't seem to get it to open, but it is on page 166 in the S4 submitted to the SEC.
Since MyMD has not yet announced any human studies to discuss, I thought it might be helpful to take a look at the proposed MILESTONE PAYMENTS in the merger agreement. It's difficult to grasp and seems to result in as many questions as it answers. The current market cap of AKER is close to 60 million. Attached is the Milestone Payment Agreement.
file:///C:/Users/rondu/OneDrive/Pictures/Scans/Scan_20210315.pdf
Jonnie must have a passion for breeding rabbits that has somehow translated into breeding companies. Fascinating to watch.
Looks like all these companies have as their principle address MyMD's suite at Johns Hopkins.
I'm flabbergasted, so don't know what to say!
https://www.flcompany.info/companies/P21000016093/
Here is yet another new FL company whose principle address is MyMD's suite at Johns Hopkins
https://www.flcompany.info/companies/P21000016093/
knuts4oe, grateful for your research - substantial findings validating my long-standing intuition that Williams is up to something important and that it will somehow (through underground hidden channels) make its way into the merger and finally emerge as an extraordinarily interesting MYMD.
This intuition is supported by occasional conversations with Patrick Cox, a researcher I respect, who keeps a good watch on what Williams is doing.
That's fascinating. Thanks!
Everyone seen this -
https://www.mymd.com/pipeline/mymd-1
At the risk of repetition just noticed that a new company started in 2021 by Jonnie and associates, named Nemo Life Sciences is located in the same Johns Hopkins Life Sciences building as MyMD Pharma. Noticed also that its suite number ended in .5 which indicates it may be in the same suite as MyMD.
Also found this read on NEMO.
While we can rule out Covid-19 as the delay involved in this merger, the fact that the S-4 submitted to the SEC explaining the merger is 630 pages long, just might indicate how complex this merger is!
On another note, MyMD Pharma, just before the merger takes place, will issue nearly 34 million of its shares to shareholders of Supera Pharma, thereby acquiring Supera. Supera was begun by Jonnie R Williams and associates.
As you know, the company never said it would be faster than this. I've posted their first news release on the merger, in which they said it would happen in mid-2021, or maybe first half of 2021.
I'm willing to assume that this is complicated and that there are a lot of moving parts that have to be approved by lawyers and accountants. This never happens as fast as we think it should.
I've been waiting for a very simple letter from a small bank. They see no problem writing the letter, but I've been waiting for it for over a month. They say the slowdown is due to the virus. Possibly so.
$AKER
The reverse merger with MYMD paper work submission date was on Jan 15th,2021.. why it is taking so much time for this small company?
This is ridiculous... laughable....
Followers
|
90
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2221
|
Created
|
01/15/15
|
Type
|
Free
|
Moderators |
Akers Biosciences mission is dedicated to solving global health challenges. Akers was founded in 1989 and has over
30 years of success in the health diagnostic industry having developed proprietary, in vitro diagnostic technologies.
In March of 2020, in an attempt to further their mission, Akers announced a strategic partnership with Premas Biotech.
The partnerships primary objective is to focus on novel vaccine candidates.
The emergence of this pandemic offers an opportunity for the company to be a solution in the healthcare space,
one that sets the stage for our next chapter of growth.
Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate
Premas develops novel & transformational technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates.
Akers licensed a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform, D-Crypt™.
The Premas platform has three key advantages which will set this vaccine candidate apart from industry peers.
Premas successfully cloned three Coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) in the first quarter of 2020 which further differentiates our vaccine candidate.
We aim to provide the immune system with several opportunities to identify the virus; a design concept extremely important for efficacy and our future success.
We held a conference call with Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, in late March.
The transcript, which provides additional information on our philosophy and milestone timeline, can be accessed here.
PIFA® technology is a cutting-edge, patented immunoassay method which rapidly, easily, and accurately detects target antigens or antibodies.
PIFA® technology is based on the selective filtration of microparticles in response to antibody/antigen binding.
Dyed microparticles coated with antigens or antibodies determine the visual signal for the results of the assay.
The presence of a corresponding antibody or antigen in the test sample results in the formation of a matrix of microparticles, which are more susceptible to filtration.
The inability of these matrixed microparticles to move through the filter, and the resulting color change in the reagent mixture,
signal positive reactivity of the test sample (e.g. the presence of target antigens or antibodies).
Key features of PIFA® technology make it advantageous for a broad array of uses:
PIFA® technology is currently used in:
Licensing Availability
PIFA® technology is available for licensing. To inquire about licensing or for technical inquiries, please contact us.
Patent Information
Shs Outstand | 8.72M
|
Insider Trans | -0.83%
|
Book/sh | 2.96 |
Cash/sh | 2.00 |
Debt/Eq NO DEBT | 0.00 |
52W Range | 1.55 - 12.72 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |